The reorganization and strengthening of LRRI has been very successful, especially in view of the tight, highly competitive research funding environment in which it has occurred.
LRRI scientists work in a wide range of broad research disciplines, including:
LRRI is committed to improving public health by preventing, treating, and curing respiratory disease.
LRRI publishes Breathe magazine to educate supporters, clients, and the public about their mission and their successes.
To reach our objective of more effectively integrating technology into our operations, we were faced with the options of either upgrading our existing data collection system, or alternatively acquiring a new comprehensive solution," comments Doug White, Chief Information Officer at LRRI.
Using the TRP[TM] solution, LRRI will now have the ability to plan entire programs or single studies managing all of the required resources according to specific skills and/or departmental workloads.
LRRI will also benefit from Instem's live global support teams, client managers and customer advocates to help optimize their technology to ensure they and their sponsors quickly see the benefits of Provantis[TM].
Equipped with a broad range of technical expertise and a wealth of research capabilities, LRRI studies respiratory health issues of concern to scientists and health care experts in universities, government, industry, and patient advocacy groups.
She and her colleagues are now collaborating with LRRI
researchers to develop an animal model to test the observations that came out of that human epidemiology study.
Scientists at LRRI
are committed to eradicating respiratory diseases through research aimed at understanding their causes and biological mechanisms, eliminating exposures to causal agents, and developing more effective treatments.
President and CEO of LRRI stated, "The results we've seen to date with SinoFresh(TM) are very encouraging and gave us the confidence and enthusiasm to move forward with more rigorous in vitro studies that more closely mimic the human respiratory system.
Additionally, LRRI is assisting in the development of a protocol intended to study the virucidal efficacy of SinoFresh(TM) and CPC in vivo.